NYSE$ABT

Abbott Laboratories · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Reported strong sales and earnings growth, achieving the upper end of initial guidance for 2024 and positioned for continued growth in 2025.

Abbott's Q4 2024 results showed strong momentum with sales growth and EPS growth reaching the highest of the year. The company achieved the upper end of its initial guidance ranges for 2024 and projects continued strong growth in 2025.

  • Fourth-quarter sales increased 7.2 percent on a reported basis and 10.1 percent on an organic basis, excluding COVID-19 testing-related sales.
  • GAAP diluted EPS was $5.27, and adjusted diluted EPS was $1.34, excluding specified items.
  • Full-year 2024 sales increased 4.6 percent on a reported basis and 9.6 percent on an organic basis, excluding COVID-19 testing-related sales.
  • Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.

Headline financials

Total Revenue

$11B

Previous: $10.2B+7.2%
EPS (adj)

$1.34

Previous: $1.19+12.6%
Diluted EPS

$5.27

No prior period
Earnings before tax

$2.03B

No prior period
Gross Margin

$5.57B

No prior period
Capital Expenditures

-$720M

Previous: $755M-195.4%
Net Income

$9.23B

Previous: $1.59B+479.0%
Operating Income

$1.91B

Previous: $1.78B+7.4%
Gross Profit

$6.08B

Previous: $5.26B+15.7%
R&D Expense

$728M

Previous: $690M+5.5%

Revenue & EPS history

Abbott · Revenue · Quarterly

$11B

Q4 2024+7.2%vs Q4 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Abbott · $6.7B total across 2 segments · Q3 2023

  • Medical Devices
    $4.25B+17.5%
  • Diagnostics
    $2.45B-33.3%

Forward guidance

Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%. Abbott projects full-year 2025 adjusted operating margin to be 23.5% to 24.0% of sales. Abbott projects full-year 2025 adjusted diluted earnings per share of $5.05 to $5.25 and first-quarter 2025 adjusted diluted earnings per share of $1.05 to $1.09.

Tailwinds

  • Full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.
  • Full-year 2025 adjusted operating margin to be 23.5% to 24.0% of sales.
  • Full-year 2025 adjusted diluted earnings per share of $5.05 to $5.25.
  • First-quarter 2025 adjusted diluted earnings per share of $1.05 to $1.09.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.6%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+1.1%

Avg return

30 days after

61%

45 / 74 earnings

Positive

+10.3%

Q3 2013

Best reaction

-9.9%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.2%-8.7%-16.8%
Q4 2025-9.9%-10.3%-7.1%
Q3 2025-2.9%-2.8%-2.0%
Q2 2025-0.1%+1.4%+3.3%
Q1 2025+2.8%+2.9%+6.8%
Q4 2024+0.8%+10.8%+15.5%
Q3 2024+1.6%+0.8%-0.1%
Q2 2024-2.5%-0.7%+6.0%
Q1 2024-3.6%-2.0%-4.7%
Q4 2023-1.4%-0.5%+4.8%
Q3 2023+3.6%+4.0%+8.0%
Q2 2023+6.5%+5.3%-3.3%
Q1 2023+6.0%+6.0%+4.6%
Q4 2022-1.3%-2.4%-10.7%
Q3 2022-9.3%-6.4%-1.1%
Q2 2022+0.7%-1.3%+0.1%
Q1 2022+2.8%+0.0%-5.6%
Q4 2021-2.3%+3.4%-0.7%
Q3 2021+4.8%+6.1%+6.3%
Q2 2021+1.5%+0.7%+6.2%
Q1 2021-1.5%-1.0%-5.4%
Q4 2020+4.9%+6.8%+4.4%
Q3 2020+1.0%+0.6%+2.3%
Q2 2020+2.6%+1.5%+3.4%
Q1 2020+5.6%+3.4%-1.2%
Q4 2019+1.1%-0.2%-2.5%
Q3 2019+0.5%-0.4%+4.5%
Q2 2019+5.5%+5.9%+1.9%
Q1 2019-3.2%-2.4%-0.5%
Q4 2018-0.9%-3.4%+6.5%
Q3 2018-4.0%-3.4%+1.5%
Q2 2018+1.6%+0.6%+3.1%
Q1 2018+0.1%-1.6%+3.2%
Q4 2017+6.7%+6.9%+0.8%
Q3 2017+1.7%+1.9%+0.9%
Q2 2017+2.9%+2.8%-1.4%
Q1 2017+1.3%+1.6%-0.6%
Q4 2016+1.6%+1.6%+12.5%
Q3 2016-1.0%-1.8%-3.2%
Q2 2016+3.0%+3.9%+5.8%
Q1 2016+0.1%
Q4 2015-6.5%
Q3 2015+4.2%
Q2 2015+2.9%
Q1 2015+2.8%
Q4 2014+3.1%
Q3 2014+0.1%
Q2 2014+1.8%
Q1 2014+2.5%
Q4 2013-4.3%
Q3 2013+10.3%
Q2 2013+0.0%
Q1 2013+1.3%
Q4 2012-0.3%
Q3 2012-7.6%
Q2 2012-1.0%
Q1 2012-1.5%
Q4 2011-0.2%
Q3 2011-0.4%
Q2 2011-0.1%
Q1 2011+0.9%
Q1 2008+1.4%
Q4 2010+1.4%
Q3 2010-0.8%
Q2 2010+0.7%
Q1 2009-1.4%
Q1 2010+0.9%
Q4 2007-1.1%
Q4 2009-1.1%
Q3 2008+1.4%
Q3 2009+1.4%
Q2 2009+2.1%
Q4 2008+2.1%
Q2 2008+2.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro